Best Diversified Diagnostics Companies in China
The 93 best Diversified Diagnostics companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Chemclin.
Tracking the strongest Diversified Diagnostics companies in China by disclosed equity funding, this directory covers 93 companies and $962M in total capital raised. Chemclin leads the field at $313M, followed by Shanghai Kehua Bio-engineering at $262M and Virtue Diagnostics at $130M. That top-three concentration tells you something: funding here isn't evenly spread, it pools around companies with broad test-menu coverage and manufacturing scale. The global diversified diagnostics market sat at roughly $3.0B in 2021 and is forecast to reach $4.5B by 2030, a 4.7% CAGR that looks modest until you factor in China's accelerating health expenditure and chronic-disease burden.
So what's actually moving the sector right now? Hot themes I'm watching include cancer biomarkers, culture-independent diagnostics, and biomarker discovery, all of which reward companies that can clear stringent regulatory approvals across multiple product lines simultaneously. Investors like Legend Capital, Lilly Asia Ventures, and Fortune Capital are clearly betting on that complexity as a moat. Point-of-care testing demand is the underlying pressure pushing the whole stack forward, and the companies that win will be the ones that can move fast without tripping over approval timelines. No unicorns in this cohort yet, but with Yueer Gene at $50M and Phase Scientific at $36M still climbing, the field isn't settled.
- ResearchAndMarkets.com
Ranked: Best Diversified Diagnostics companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Anjue Medical Manufacturer and supplier of medical and diagnostic equipment | — | — | Unfunded | — | Jonathan Dong CEO | — | — | — |
| 2 | Athena Lab Technology Manufacturer of rapid diagnostic test | — | — | Unfunded | — | David CEO | — | — | — |
| 3 | Attobio Provider of an in vitro testing service. The company specializes in in vitro diagnostics and testing… | — | — | Private | 15 | — | — | — | — |
| 4 | Autobio Diagnostics Manufacturer of diagnostic reagents and instruments for clinical laboratories | — | — | Funding Raised | 5,505 | Zeng Yang CEO | PHPAnimate.cssVideoJS+8 | 56 patents Clinical immunoassay reagents and sample preparation for chemiluminescent diagnostics | — |
| 5 | Beijing Savant Biotechnology Develops and markets IVD products | — | — | Funding Raised | 301 | — | — | — | — |
| 6 | Beijing Unidiag Technology Provider of chemiluminescence immunoassay | — | — | Funding Raised | — | Xie Yuandong CEO | — | — | — |
| 7 | Best Medical R&D company manufacturing medical imaging and radiation therapy products | — | — | Funding Raised | 310 | David Shi CEO | — | — | — |
| 8 | Biosino Biotechnology & Science Manufacturer of IVD products | — | — | Unfunded | — | Chen Jintian CEO & President | — | — | — |
Top 12 Diversified Diagnostics companies in China
#1
Series A · Hong Kong, Hong Kong · founded 2012 · 20 employees$36Mraised▾
Phase Scientific provides the technology for diagnostics tools. It offers its propriety point-of-care test kits for infectious diseases, including tooth decay, hepatitis, malaria, and sexually transmitted diseases, liquid biopsy for an early stage of cancer determination, it also offers health data platform and mobile app connected to a database and analytical to manage health risks. It also offers animal health, food safety, and environmental testing.
- May 2025Series A$34M
- May 2017Grant (prize money)$749.8K
- Mar 2017Grant (prize money)$1.1M
- Jan 2016Grant (prize money)$150K
#2
Public · Suzhou, Jiangsu · founded 2007 · 488 employees$13.7Mraised▾
IVD products for clinical immune diagnosis
- Nov 2023Post IPO$13.7M
#3
Series B · Suzhou, Jiangsu · founded 2019 · 500 employees$130Mraised▾
Provider of an in vitro assay platform for diagnostic solutions. The company's technology can be used for early screening, diagnosis, treatment/monitoring and management of the minimal residual disease. The technology can be used in a variety of diseases such as infectious disease, cancer, maternal and fetal health, and chronic disease.
- Jan 2022Series B$100M
- Dec 2020Series A$30M
#4
Acquired · Beijing, Beijing · founded 2007 · 658 employees$312.5Mraised▾
Beijing Chemclin Biotech Co is a fully-owned subsidiary of the China Diagnostics Medical Corporation, a leading diagnostic company that specializes in the development, manufacturing and distribution of In Vitro Diagnostic reagents and instruments. The company develops diagnostic reagents covering chemiluminescence immunoassays, radioimmunoassay, and clinical chemistry assays. It provides radioimmunoassay or immunoradiometric assay kits as well as chemiluminescence immunoassay systems for in-vitro diagnostics, such as reagents, infectious diseases, tumor markers, liver fibrosis, diabetes, thyroid, and fertility.
- Aug 2018Series C$292M
- Oct 2008Series B$16.5M
- Apr 2007Series A$4M
#5
Series B · Yangpu, Shanghai · founded 2016$50Mraised▾
R&D company manufacturing diagnostic products
- Jun 2022Series B$50M
#6
Public · Shanghai, Shanghai · founded 1998 · 2709 employees$262Mraised▾
Shanghai Kehua Bio-engineering develops, manufacturers and markets a variety of in vitro diagnostic products. Its product line includes Chemiluminescent Immunoassays, Enzyme-Immunoassay kits, Clinical chemistry reagents, PCR kits, Rapid test kits, Chemiluminescence reagents, Chemistry analyzer, Electrolyte analyzer, Automatic Chemiluminescence analyzer, and Microplate washer.
- Jan 2014PE$262M
#7
Series D · Nanjing, Jiangsu · founded 2016$14.2Mraised▾
Lansion Biotechnology provides microfluidics-based in vitro diagnostic reagents and instruments. The company offers devices like incubators, molecular diagnostic analyzers, fluorescence immunoassay analyzers, immunochromatographers, etc. The company has ISO13485 certificate.
- Sep 2022Series D—
- 2022Series D—
- Dec 2020Series D—
- Nov 2019Series C$14.2M
#8
Series C · Beijing, Beijing · founded 2017 · 200 employees$29.6Mraised▾
Manufacturer of pathology and diagnostic products
- Sep 2021Series C$15.5M
- Jun 2020Series B$14.1M
#9
Series B · China · founded 2011 · 2284 employees$75Mraised▾
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
#10
Series B · Hefei, Anhui · founded 2013$9.4Mraised▾
R&D company manufacturing tumour diagnosing drugs
- Dec 2021Series B—
#11
Seed · Nanjing, Jiangsu · founded 2017 · 100 employees$6.2Mraised▾
Developer and manufacturer of in-vitro diagnostic instruments and reagents for medical and veterinary use. It provides diagnostic solutions, including instruments and reagents, for medical and veterinary applications. The company develops and produces diagnostic tests for inflammation, metabolism, anemia, hormones, hypertension, thyroid function, cytokines, prenatal screening, cardiovascular conditions, and infectious diseases. It also offers dry chemistry luminescence ODM services and freeze-dried microsphere CDMO services, along with related products for drug testing, food testing, livestock monitoring, environmental monitoring, and medical aesthetics.
- Aug 2021Seed$6.2M
#12
Series A · Hangzhou, Zhejiang · founded 2010$8.7Mraised▾
R&D company manufacturing molecular diagnostics biomarkers, assays, and devices
- May 2020Series A$8.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Diagnostics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.